ArticleFrontiers in cellular and infection microbiology2025
Retrospective cohort analysis on predicting pulmonary fibrosis in elderly SARS-CoV-2-infected patients.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: SARS-CoV-2 exhibits rapid transmission with a high susceptibility rate, particularly among the elderly. Pulmonary fibrosis (PF) following SARS-CoV-2 infection is a life-threatening complication. However, predictive models for PF in older patients are lacking. Methods: Data from patients with COVID-19 aged 60 and above, collected retrospectively between November 2022 and November 2023 across two independent hospitals, were analyzed. Patients from Tangdu Hospital were divided into training and validation cohorts using a 7:3 allocation ratio, while those from The 940th Hospital of the Joint Logistics Support Force of the People's Liberation Army (PLA) served as the test cohort. Identify the most valuable predictors (MVPs) for PF using Least Absolute Shrinkage and Selection Operator (LASSO) regression, and construct a nomogram based on their regression coefficients derived from logistic regression. The calibration, clinical utility, and discriminatory ability of the nomogram were evaluated using the Hosmer-Lemeshow test, decision curve analysis (DCA), and Receiver Operating Characteristic (ROC) curve, respectively. Results: Neutrophil percentage, C-reactive protein (CRP), gender, diagnostic classification, and time from symptom onset to hospitalization were identified as the MVPs for PF. The nomogram was developed based on these predictors, In all the three cohorts, the nomogram showed good calibration, clinical utility and discriminatory ability, with Area Under the Curve (AUC) of 0.777, 0.735 and 0.753, respectively. Furthermore, based on the principle of optimizing the balance between sensitivity and specificity, 131.026 was determined as the optimal cutoff value for the nomogram. Accordingly, patients with a nomogram score of 131.026 or higher were classified into the high-risk group. Conclusions: This study presents the first nomogram for predicting PF in elderly patients following SARS-CoV-2 infection, which may serve as a clinical tool for risk assessment and early management in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.